GE HealthCare has delivered the initial subject doses of Flyrcado (flurpiridaz F 18) injection, for coronary artery disease ...

GE HealthCare (GEHC) has delivered the first patient doses of Flyrcado or flurpiridaz F 18 njection, a first-of-its-kind unit dose positron ...

Patients undergo first doses of GE HealthCare's PET radiotracer Flyrcado (flurpiridaz F 18) injection at early adopter sites ...

Advance Auto (NYSE:AAP), and Freshworks (NASDAQ:FRSH) to its portfolio in Q4 2024, while exiting Smartsheet (SMAR), CBRE (NYSE:CBRE), and Monday.com (NASDAQ:MNDY), it disclosed in its 13F filing on ...

Revenue: $5.3 billion for Q4 2024, with organic growth of 2%. Service Revenue Growth: 6% increase on a reported basis in Q4 2024. Product Revenue Growth: 1% increase on a reported basis in Q4 2024.

The company announced the planned launch of Flyrcado, a radiopharmaceutical product for myocardial perfusion imaging, in April 2025. It is expected to generate $30 million in revenue for 2025 and ...

ARLINGTON HEIGHTS, Ill. - GE HealthCare (NASDAQ: NASDAQ:GEHC) has received U.S. Food and Drug Administration (FDA) approval for Flyrcado™ (flurpiridaz F 18) injection, a new... ByInvesting.com • Sep ...

The state’s life sciences industry honored its own last Thursday night at BioNJ’s annual Dinner Meeting & Innovation Celebration. Held at the Hilton East Brunswick, the gala represented a who’s who of ...

ARLINGTON HEIGHTS, Ill. - GE HealthCare (NASDAQ: NASDAQ:GEHC) has received U.S. Food and Drug Administration (FDA) approval for Flyrcado™ (flurpiridaz F 18) injection, a new... ByInvesting.com ...

Eyeing an expected leap in demand for contrast media—used in X-rays, CT scans and more—GE HealthCare is upping its stake in the Emerald Isle. The company is pumping $138 million into its ...